Collegium Pharmaceutical, Inc. reports developments for a diversified biopharmaceutical business focused on commercial medicines for serious medical conditions. Its recurring news centers on JORNAY PM for ADHD, a neuropsychiatry growth business, and a responsible pain management portfolio that includes BELBUCA, Xtampza ER, Nucynta products and Symproic.
Company updates also cover operating and financial results, investor presentations, real-world data from pain medications, branded ADHD awareness campaigns, capital deployment, credit facilities, material agreements, shareholder voting matters and governance disclosures.
Collegium Pharmaceutical, Inc. (Nasdaq: COLL) has announced an authorized generic agreement with Hikma Pharmaceuticals USA Inc. for Nucynta® and Nucynta® ER, bolstering the value of the Nucynta Franchise through 2025 and beyond. Collegium will manufacture and supply Hikma with authorized generic products, with Hikma having exclusive rights to sell them in the U.S. Collegium will receive a share of net profits based on the number of generic entrants.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.